David Boulware

David Boulware is a Professor in the Department of Medicine at the University of Minnesota Medical School, with cross-appointments in the Division of Infectious Diseases and International Medicine, Microbiology/Immunology/Cancer Biology Graduate Program, and Division of Epidemiology and Community Health. He serves as a preceptor for the Medical Scientist Training Program (MD/PhD) and maintains active clinical and research roles within the institution.

His research focuses on infectious disease pathogenesis and clinical management, particularly cryptococcal meningitis in HIV patients, tuberculous meningitis, and outpatient COVID-19 therapeutics. Key interests include optimizing antifungal regimens in resource-limited settings, neuroimmunology of CNS infections, and decentralized clinical trial methodologies. His work emphasizes practical solutions for global health challenges, with extensive field research in Uganda and sub-Saharan Africa.

Recent publications demonstrate leadership in high-impact clinical trials: the ACTIV-6 platform for repurposed COVID-19 therapeutics (including metformin, fluvoxamine, and ivermectin), implementation of single-dose liposomal amphotericin regimens for cryptococcal meningitis, and development of prognostic tools for meningitis mortality. His research integrates laboratory science with implementation challenges in low-resource environments.

Scientific recognition includes:

• Principal investigator for multiple NIH-funded clinical trials
• Contributor to global cryptococcosis management guidelines
• Extensive publication record in high-impact infectious disease journals

Boulware directs significant research operations in Uganda, focusing on meningitis management in advanced HIV disease. His team investigates diagnostic innovations, economic impacts of opportunistic infections, and neurocognitive outcomes. He actively mentors through the Medical Scientist Training Program and collaborates with international consortia including the Infectious Diseases Society of America and international HIV research networks. Current work emphasizes scalable interventions for cryptococcal disease in Africa and adaptive trial designs for emerging pathogens.